Last reviewed · How we verify
Vasopressin; Methylprednisolone; Hydrocortisone
Vasopressin; Methylprednisolone; Hydrocortisone is a Vasopressin is a hormone, specifically a nonapeptide. Small molecule drug developed by Tiohundra AB. It is currently in Phase 3 development for Hemorrhagic shock, Septic shock, Diabetes insipidus, Central diabetes insipidus.
Vasopressin is a hormone that causes blood vessels to constrict, increasing blood pressure.
Vasopressin is a hormone that causes blood vessels to constrict, increasing blood pressure. Used for Hemorrhagic shock, Septic shock, Diabetes insipidus, Central diabetes insipidus.
At a glance
| Generic name | Vasopressin; Methylprednisolone; Hydrocortisone |
|---|---|
| Sponsor | Tiohundra AB |
| Drug class | Vasopressin is a hormone, specifically a nonapeptide. |
| Target | Vasopressin receptor 1A (V1A), Vasopressin receptor 2 (V2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular, Nephrology |
| Phase | Phase 3 |
Mechanism of action
Vasopressin works by binding to vasopressin receptors in the body, which triggers a cascade of events leading to vasoconstriction and increased blood pressure. This can be beneficial in certain medical conditions, such as septic shock. However, excessive vasopressin can have negative effects, including vasoconstriction in other areas of the body.
Approved indications
- Hemorrhagic shock, Septic shock, Diabetes insipidus
- Central diabetes insipidus
Common side effects
- Hypertension
- Nausea
- Headache
- Dizziness
- Flushing
- Tachycardia
- Bradycardia
- Hypotension
- Cardiac arrest
- Arrhythmia
Key clinical trials
- Arterial Pressure and Stress-Dose Steroids in Cardiac Arrest.
- VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial (PHASE3)
- Vasopressin, Epinephrine, and Steroids for Cardiac Arrest (PHASE3)
- Combined Vasopressin, Methylprednisolone, and Epinephrine for Inhospital Cardiac Arrest (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vasopressin; Methylprednisolone; Hydrocortisone CI brief — competitive landscape report
- Vasopressin; Methylprednisolone; Hydrocortisone updates RSS · CI watch RSS
- Tiohundra AB portfolio CI
Frequently asked questions about Vasopressin; Methylprednisolone; Hydrocortisone
What is Vasopressin; Methylprednisolone; Hydrocortisone?
How does Vasopressin; Methylprednisolone; Hydrocortisone work?
What is Vasopressin; Methylprednisolone; Hydrocortisone used for?
Who makes Vasopressin; Methylprednisolone; Hydrocortisone?
What drug class is Vasopressin; Methylprednisolone; Hydrocortisone in?
What development phase is Vasopressin; Methylprednisolone; Hydrocortisone in?
What are the side effects of Vasopressin; Methylprednisolone; Hydrocortisone?
What does Vasopressin; Methylprednisolone; Hydrocortisone target?
Related
- Drug class: All Vasopressin is a hormone, specifically a nonapeptide. drugs
- Target: All drugs targeting Vasopressin receptor 1A (V1A), Vasopressin receptor 2 (V2)
- Manufacturer: Tiohundra AB — full pipeline
- Therapeutic area: All drugs in Cardiovascular, Nephrology
- Indication: Drugs for Hemorrhagic shock, Septic shock, Diabetes insipidus
- Indication: Drugs for Central diabetes insipidus
- Compare: Vasopressin; Methylprednisolone; Hydrocortisone vs similar drugs
- Pricing: Vasopressin; Methylprednisolone; Hydrocortisone cost, discount & access